Steadybase.

Latigo Biotherapeutics, Inc.

Website Investor relations LinkedIn
  • LTGO · Nasdaq
  • Pharmaceutical Preparations
  • Thousand Oaks, CA
  • CIK 0002056611

Updated from SEC filings through

Top things to know

Executives

What leadership is saying

“With the proceeds from our IPO, we are well-positioned to continue to execute across our development plans for onzotrigine and LTG-321. For onzotrigine, the addition of a Percocet arm to our Phase 3 bunionectomy trial is intended to provide further support for onzotrigine as an opioid-free pain management option in a second surgical model, while also providing data against a commonly used opioid comparator distinct from the one evaluated in our abdominoplasty program”

Todd N. Smith, President and chief executive officer, Latigo
Earnings press release (8-K Ex. 99.1), filed November 5, 2026

Latigo Biotherapeutics, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Thousand Oaks, CA. It trades as LTGO on Nasdaq. Todd N. Smith is President and CEO.

Five-year financials

We have no annual financials for this company yet.

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Todd N. Smith President and CEO Form 4, November 18, 2026
Nima Farzan President and CEO Form 3, August 6, 2026
Neha Krishnamohan Neha Krishnamohan
CFO & CBO Latigo Biotherapeutics | Board Member | GS Alum
CFO and Chief Business Officer Form 3, August 6, 2026
Neil Singla
Chief Medical Officer at Latigo Biotherapeutics
Chief Medical Officer Form 3, August 6, 2026

What Latigo Biotherapeutics, Inc. does

Disrupt Pain Without Opioids. While other treatments dull pain, Latigo’s solutions target the source of pain before it reaches the central nervous system. The result is healing without dependence, and relief that can help restore quality of life.

Company website description, 10-K for the year ending November 7, 2026

Shares and governance

Shares outstanding 66.3 million (as of November 2, 2026) 10-Q, November 5, 2026
Reportable segments 1 (period ending June 30, 2026) 10-Q, September 3, 2026

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
August 10, 2026 James B. Tananbaum
Director
Buy 140,000 $2.5M Form 4, August 10, 2026

Recent 8-K events

  • 8-K filed 2026-11-05
    • Item 2.02 Results of operations and financial condition (earnings release)
    • Item 5.02 Departure or appointment of directors or officers; compensation
  • 8-K filed 2026-09-03
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-08-10
    • Item 5.03 Amendments to articles or bylaws; change in fiscal year
    • Item 8.01 Other events

Frequently asked questions about Latigo Biotherapeutics, Inc.

What does Latigo Biotherapeutics, Inc. do?
In its own words, from Item 1 of its 10-K: "Disrupt Pain Without Opioids. While other treatments dull pain, Latigo’s solutions target the source of pain before it reaches the central nervous system. The result is healing without dependence, and relief that can help restore quality of life."
Who is the CEO of Latigo Biotherapeutics, Inc.?
Todd N. Smith, President and CEO, as named in a 4 filed November 18, 2026.
Who is the CFO of Latigo Biotherapeutics, Inc.?
Neha Krishnamohan, CFO and Chief Business Officer, as named in a 3 filed August 6, 2026.
Where is Latigo Biotherapeutics, Inc. headquartered?
Thousand Oaks, CA.
What is Latigo Biotherapeutics, Inc.'s stock ticker?
LTGO on Nasdaq.
What industry is Latigo Biotherapeutics, Inc. in?
Pharmaceutical Preparations, SIC code 2834.
What is Latigo Biotherapeutics, Inc.'s website?
latigobio.com. Investor relations: https://investors.latigobio.com/.
When does Latigo Biotherapeutics, Inc. report earnings next?
December 3, 2026. Source: pg_earnings_events.
Is Latigo Biotherapeutics, Inc. a public company?
Yes. Latigo Biotherapeutics, Inc. files with the SEC under CIK 0002056611 and trades as LTGO.
How many shares of Latigo Biotherapeutics, Inc. are outstanding?
66.3 million shares as of November 2, 2026, from its 10-Q filed November 5, 2026.
How many business segments does Latigo Biotherapeutics, Inc. report?
1 reportable segment for the period ending June 30, 2026, from its 10-Q filed September 3, 2026.
Have Latigo Biotherapeutics, Inc. insiders traded stock recently?
Since August 10, 2026, officers and directors reported 0 open-market sales and 1 purchase worth about $2.5M on Forms 4 and 5. The most recent: James B. Tananbaum (Director) bought 140,000 shares on August 10, 2026.